Offer your patients cutting-edge cancer treatment options
As a clinician, referring your patients to clinical trials can provide them with access to cutting-edge therapies that are not yet available in standard care. These trials are critical in evaluating the safety and efficacy of innovative treatments.
Participation in early phase trials has more potential for clinical benefit than is commonly believed, largely due to the development of modern cancer drugs, like targeted therapies, immunotherapies, and new combination therapies.
With internationally recognised Medical Directors, Professor Michael Millward and Professor Chan Cheah, overseeing Linear’s cancer clinical trials, there are multiple ways to partner with Linear to provide your patients access to clinical trials and engage seamlessly with the leading biopharmaceutical companies from around the world.
Refer a patient
Offer your patients cutting-edge cancer treatment options. Please see our referral form to start the process.
Supporting you in advancing cancer research and care
Diverse trial portfolio
Spanning a wide range of indications, our trials feature various innovative approaches, including immunotherapies, targeted treatments, combination regimens, and CAR-T cell therapy.
World-class facilities
Equipped with state-of-the-art technology and resources, the Advanced Clinical Trials Centre (ACTC) is able to admit eighteen participants with six overnight capabilities.
Dedicated investigator support
Full operational and regulatory support to streamline research and patient care.
Ready to make an impact as a trial investigator?
Becoming a principal investigator in phase 1 clinical trials opens a unique path to advancing both your career and the field of cancer. While Phase 1 trials may seem daunting due to administrative demands or safety concerns, our dedicated team is here to support you every step of the way. We handle the logistics, streamline processes, and maintain rigorous safety protocols, allowing you to focus on what matters most—leading impactful research that benefits patients and builds a legacy in cancer care.
Cancer trials currently running at Linear
Advanced Solid Tumours
GO43860
A Phase Ia/Ib, Open Label, Multicenter, Dose-escalation Study to Evaluate the Safety, Pharmacokinetics, and Activity of RO7502175 as a Single Agent and in Combination With Atezolizumab in Patients With Locally Advanced or Metastatic Solid Tumors
Solid Tumours with Activating FGFR3 Gene Alterations
TYR300-101
A Multicenter, Open-label Phase 1/2 Study of TYRA-300 in Advanced Urothelial Carcinoma and Other Solid Tumors with Activating FGFR3 Gene Alterations (SURF-301)
KRAS G12C-Mutant Advanced Solid Tumours
LOXO RAS-20001
A Phase 1a/1b Study of LY3537982 in Patients With KRAS G12C-Mutant Advanced Solid Tumors
Advanced Solid Tumours
BGB-A317-26808-101
A Phase 1 Study Investigating the Safety, Tolerability, Pharmacokinetics, and Preliminary Antitumor Activity of HPK1 Inhibitor BGB-26808 Alone or in Combination With Anti-PD-1 Monoclonal Antibody Tislelizumab in Patients With Advanced Solid Tumors
Advanced PRAME-Positive Cancers
IMC-F106C-101
A Phase 1/2 First-in-Human Study of the Safety and Efficacy of IMC-F106C as a Single Agent and in Combination with Checkpoint Inhibitors in HLA-A*02:01-Positive Participants with Advanced PRAME-Positive Cancers
Advanced Solid Tumours Harboring NRG1 Fusions
HMBD-001-102
A Phase 1b study to evaluate HMBD-001 with or without chemotherapy in participants with advanced solid tumours harboring NRG1 fusions
Advanced Squamous Non Small Cell Lung Cancer
HMBD-001-103
A Phase 1b study to evaluate HMBD-001 in combination with docetaxel with or without cetuximab in participants with advanced squamous non small cell lung cancer
Solid Tumors Harboring a TP53 Y220C Mutation
PMV-586-101
A Phase 1/2 Open-label, Multicenter Study to Assess the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics, and Efficacy of PC14586 in Patients with Locally Advanced or Metastatic Solid Tumors Harboring a TP53 Y220C Mutation (PYNNACLE)
Advanced Solid Tumours
BGB-283/PD-0325901
A Phase 1b, Open-Label, Dose-escalation and Expansion Study to Investigate the Safety, Pharmacokinetics and Antitumor Activities of a RAF Dimer Inhibitor BGB-283 in Combination With MEK Inhibitor PD-0325901 in Patients With Advanced or Refractory Solid Tumors
Metastatic Triple-Negative Breast Cancer
CO42867
A Phase Ib/II, Open-Label, Multicenter, Randomized Umbrella Study Evaluating The Efficacy And Safety Of Multiple Immunotherapy-Based Treatment Combinations In Patients With Metastatic Triple-Negative Breast Cancer (Morpheus-TNBC)
Metastatic Castration-Resistant Prostate Cancer
PSMA-007-001
A Phase 1, Open-Label, Multicenter Study of JANX007 in Subjects With Metastatic Castration-Resistant Prostate Cancer
Advanced Solid Tumours
AXA-042-FIH-01
A Phase 1a/1b, first-in-human, open-label, non-randomized, multicenter, dose-escalation and dose-expansion study to evaluate the safety, tolerability, pharmacokinetics, and pharmacodynamics of AXA-042 as monotherapy and in combination with checkpoint inhibitors in subjects with advanced solid tumors
Advanced Solid Tumours
IOS-1002-201
A Phase 1a/1b, First-in-human, Open-label, Non-randomized, Multicenter, Dose-escalation and Cohort Expansion Study to Evaluate the Safety, Tolerability, Efficacy, Immunogenicity, Pharmacokinetics, and Pharmacodynamics of IOS-1002 Administered Alone and in Combination With a PD-1 Monoclonal Antibody in Advanced Solid Tumors
Advanced Solid Tumours
BGB-A317-A3055-101
A Phase 1a/1b Study Investigating the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics, and Preliminary Antitumor Activity of BGB-A3055, Alone and in Combination With Tislelizumab in Patients With Selected Advanced or Metastatic Solid Tumors
HER2 Expressing Advanced Solid Tumours
IKS014-01
An open-label, single-arm, Phase 1a/1b study with a 3+3 dose escalation phase, which evaluates FS-1502 (IKS014) in patients with HER2 expressing advanced solid tumors (Phase 1a) followed by an expansion cohort (EC) in HER2+ breast cancer (BCa) (Phase 1b)
KRAS G12D-Mutant Advanced Solid Tumours
INCB 161734-101
A phase 1, open-label, multicenter study of INCB161734 in participants with advanced or metastatic solid tumours with KRAS G12D mutation
Selected HER2 Expressing Tumours
DESTINY-PanTumor02
A Phase 2, Multicenter, Open-label Study to Evaluate the Efficacy and Safety of Trastuzumab Deruxtecan (T-DXd, DS-8201a) for the Treatment of Selected HER2 Expressing Tumors (DESTINY-PanTumor02)
Advanced Solid Tumours
CLN-619-001
A Phase 1 Dose-Escalation Study to Investigate the Safety, Efficacy, Pharmacokinetics, and Pharmacodynamic Activity of CLN-619 (Anti-MICA/MICB Antibody) Alone and in Combination With Pembrolizumab in Patients With Advanced Solid Tumours
BRAF and/or NRAS Mutation-positive Solid Tumours
KN-8701
A Phase 1/1b Open-label, Multicenter Study to Investigate the Safety, Tolerability, Pharmacokinetics, and Antitumor Activity of KIN-2787 in Participants With BRAF and/or NRAS Mutation-positive Solid Tumors
HER2 Mutant Non-Small Cell Lung Cancer
ELVN-002-001
A Phase 1a/1b Study of ELVN-002 for the Treatment of Patients With HER2 Mutant Non-Small Cell Lung Cancer
Advanced Solid Tumours
D6900C00001
A Phase I/IIa Multi-center, Open-label Master Protocol to Evaluate the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics and Preliminary Antitumor Activity of AZD8205 in Participants with Advanced or Metastatic Solid Malignancies
Advanced Solid Tumours
DCSZ11-101
A Phase 1, Multicenter, Open-Label, Dose Escalation, and Dose Expansion Study to Assess the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics, and Antitumor Activity of DCSZ11 as a Monotherapy in Patients with Advanced or Metastatic Solid Tumors
Advanced Solid Tumours
DB-1311-O-1001
A Phase 1/2a, Multicenter, Open-Label, First in Human Study to Assess the Safety, Tolerability, Pharmacokinetics, and Preliminary Antitumor Activity of DB-1311 in Subjects with Advanced/Metastatic Solid Tumors
Advanced or Metastatic Epithelial Tumours
MTX-TROP2-302
A Phase 1, Open-Label, First-in-Human, Dose Escalation Study to Investigate the Safety, Pharmacokinetics, Pharmacodynamics and Preliminary Efficacy of MT-302 in Adults With Advanced or Metastatic Epithelial Tumors
Mutant NF2 or mNF2 Advanced Solid Tumours
VT3989-001
Phase 1, Multi-Center, Open-Label Study of VT3989 in Patients with Refractory Locally Advanced or Metastatic Solid Tumors Enriched for Tumors Harboring Mutations of the Neurofibromatosis Type 2 Gene (mutant NF2 or mNF2)
Advanced Solid Tumours
GSK217228
A Phase 1 First-Time-in-Human, Open-Label Study of GSK4381562 Administered as Monotherapy and in Combination With Anticancer Agents in Participants With Selected Advanced Solid Tumors
Advanced Solid Tumours with MAPK Pathway Mutations
D3S-002-100
A Phase 1, Open-label, Dose-escalation Study Evaluating the Safety, Tolerability, Pharmacokinetics, and Recommended Phase 2 Dose of D3S-002 Monotherapy in Adult Subjects with Advanced Solid Tumors with MAPK Pathway Mutations
Advanced Solid Tumours
BGB-A317-30813-101
A Phase 1a/1b Study Investigating the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics, and Preliminary Antitumor Activity of the DGKζ Inhibitor BGB-30813, Alone or in Combination With the Anti-PD-1 Monoclonal Antibody Tislelizumab in Patients With Advanced or Metastatic Solid Tumors
Advanced Solid Tumors with a KRAS p.G12C Mutation
D3S-001-100
A Phase 1, Open-label, Dose-escalation and Dose-expansion Study Evaluating the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics, and Preliminary Efficacy of D3S-001 Monotherapy in Subjects with Advanced Solid Tumors with a KRAS p.G12C Mutation
Advanced Solid Tumours
BG-C9074-101
Phase 1a/1b Study of BG-C9074, an Antibody Drug Conjugate Targeting B7H4, as Monotherapy and in Combination With Tislelizumab in Participants With Advanced Solid Tumors
Advanced Solid Tumours with a SMARCA4 Mutation
PRT7732-01
A Phase 1 Open-Label, Multi-Center, Safety and Efficacy Study of PRT7732 in Patients with Advanced or Metastatic Solid Tumors with a SMARCA4 Mutation
Advanced Solid Tumours with MTAP Deletion
BGB-58067-101
A Phase 1a/b Study Investigating the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics, and Preliminary Antitumor Activity of BGB-58067, an MTA-Cooperative PRMT5
Advanced Solid Tumours GPC3-Expressing Cancers
MTX-GPC3-303
A Phase 1, Open-Label, First-in-Human, Dose Escalation Study to Investigate the Safety, Pharmacokinetics, Pharmacodynamics and Preliminary Efficacy of MT 303 in Adults with Advanced or Metastatic GPC3-Expressing Cancers, including Hepatocellular Carcinoma
Advanced Solid Tumours
PTT-4256-01
A Modular, Open Label, Dose Finding Phase 1/2 Clinical Trial in Patients with Solid Cancer to Assess the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of PTT-4256
Advanced Solid Tumours
BG-T187-101
A Phase 1 Study Investigating the Safety, Tolerability, Pharmacokinetics, and Preliminary Antitumor Activity of BG-T187, an EGFR×MET Trispecific Antibody, Alone and in Combination With Other Therapeutic Agents in Patients With Advanced Solid Tumors
Advanced Solid Tumours
AMT-676-01
First-in-Human, Phase 1 Study of AMT-676, an Anti-CDH17 Antibody-Drug Conjugate, in Patients with Advanced Solid Tumors
Advanced Solid Tumours
SNV1521-101
A Phase 1, Open-Label Dose Escalation and Expansion Study of SNV1521 in Participants With Advanced Solid Tumors
Advanced Solid Tumours
DB-1419-O-1001
A Phase 1/2a Multicenter, Open-Label, First in Human Study to Assess the Safety, Tolerability, Pharmacokinetics and Preliminary Antitumor Activity of DB-1419 in Subjects with Advanced/Metastatic Solid Tumors
Advanced Urothelial Carcinoma or Other Solid Tumours
LOXO-LNC-24001
A Phase 1a/1b Study of LY4052031, a Nectin-4-targeted ADC, in Patients with Advanced or Metastatic Urothelial Carcinoma or Other Solid Tumors
Non-Hodgkin Lymphoma
GCT3013-02
A Phase 1b/2, Open-Label Trial to Assess the Safety and Preliminary Efficacy of Epcoritamab (GEN3013; DuoBody®-CD3xCD20) in Combination With Other Agents in Subjects With B-cell Non-Hodgkin Lymphoma (B-NHL)
Non-Hodgkin Lymphoma, Chronic Lymphocytic Leukemia
BGB-11417-101
A Phase 1a/1b Open-Label Dose Escalation and Expansion Study of Bcl-2 Inhibitor BGB-11417 in Patients With Mature B-Cell Malignancies
Non-Hodgkin Lymphoma, Chronic Lymphocytic Leukemia
80948543LYM1001
A Phase 1, First-in-human Study of JNJ-80948543, a T-cell Redirecting Antibody, in Participants with NHL and CLL
Non-Hodgkin Lymphoma, Chronic Lymphocytic Leukemia
BGB-16673-101
A Phase 1, Open-Label, Dose-Escalation and -Expansion Study of the Bruton Tyrosine Kinase-Targeted Protein-Degrader BGB-16673 in Patients With B-Cell Malignancies
Waldenström Macroglobulinemia
BGB-11417-203
An Open-Label, Multicenter Phase 2 Study to Evaluate the Efficacy and Safety of the BCL2 Inhibitor Sonrotoclax (BGB-11417) as Monotherapy and in Combination with Zanubrutinib (BGB-3111) in Patients With Waldenström Macroglobulinemia
Non-Hodgkin Lymphoma
IKS03-01
A Phase 1 Cohort Dose Escalation and Expansion Trial to Determine the Safety, Tolerance, Maximum Tolerated Dose, and Preliminary Antineoplastic Activity of IKS03, a CD19-Targeting Antibody Drug Conjugate (ADC), in Patients with Advanced B cell Non-Hodgkin Lymphomas (NHL)
Non-Hodgkin Lymphoma, Chronic Lymphocytic Leukemia
PRT2527-02
A Phase 1 Open-Label, Multi-Center, Safety and Efficacy Study of PRT2527 in Participants with Relapsed/Refractory Hematologic Malignancies
Non-Hodgkin Lymphoma
87801493LYM1001
A Phase 1, First-in-human Study of JNJ-87801493 in Combination with CD3 T-Cell Engagers in Participants with Relapsed/Refractory B-cell Non-Hodgkin Lymphoid Malignancies (NHLs)
Non-Hodgkin Lymphoma, Chronic Lymphocytic Leukemia
BGB-21447-101
A Phase 1 Open-Label Dose-Escalation Study of Bcl-2 Inhibitor BGB-21447 in Patients With Mature B-Cell Malignancies
Non-Hodgkin Lymphoma, Chronic Lymphocytic Leukemia
DZ2022B0002
A Phase 1, Open-label, Multicenter Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Anti-tumor Efficacy of DZD8586 in Patients with Relapsed or Refractory B-cell Non-Hodgkin Lymphoma (B-NHL)
Non-Hodgkin Lymphoma, Chronic Lymphocytic Leukemia
DR-0201-ONC-001
A Multicenter, Multiple Expansion Cohort Phase 1 Study Evaluating the Safety and Activity of DR-0201 as Multiple Ascending Doses in Patients with Relapsed/Refractory B Cell Non-Hodgkin Lymphoma
Hodgkins Lymphoma
D9971C00001
A Modular Phase I/II, Open-label, Multicentre Study to Evaluate the Safety, Tolerability, and Efficacy of AZD3470, a PRMT5 Inhibitor, as Monotherapy and in Combination With Anticancer Agent(s) in Participants With Relapsed/Refractory Haematologic Malignancies
Multiple Myeloma
218670 (DREAMM20)
A Phase 1/2 open-label, multicentre, dose escalation and expansion study to investigate the safety, tolerability, and clinical activity of belantamab as monotherapy and in combination with other treatments in participants with multiple myeloma
Multiple Myeloma
ISB 2001-101
A Phase 1, First-in-Human, Multicenter, Open-Label, Dose Escalation and Dose-Expansion Study of Single-Agent ISB 2001 in Subjects with Relapsed/Refractory Multiple Myeloma
Multiple Myeloma
D7230C00001
A Phase I/II, Open-Label, Multiple Centre Clinical Study to Evaluate the Safety, Tolerability, Pharmacokinetics, Immunogenicity and Preliminary Efficacy of AZD0305 in Patients with Relapsed or Refractory Multiple Myeloma
Acute Myeloid Leukemia, Myelodysplastic Syndrome
BGB-11417-103
A Phase 1a/1b Open-Label Dose Escalation and Expansion Study of Bcl-2 Inhibitor BGB-11417 in Patients With Mature B-Cell Malignancies
FLT3 mutated AML
ZE46-0134-0002
A Phase 1, Open-label, Dose Escalation and Dose Expansion, Multicenter Clinical Trial to Evaluate the Safety, Pharmacokinetics, Pharmacodynamics, and Preliminary Efficacy of ZE46-0134 in Adults with FLT3 mutated Relapsed or Refractory Acute Myeloid Leukemia (AML)
Polycythemia Vera
SLN124-004
Phase 1/2 study with an open-label dose escalation phase followed by a randomized, double-blind phase of SLN124 in patients with Polycythemia Vera
Advanced Solid Tumours
AMT-754-01
First-in-Human, Phase 1 Study of AMT-754, a Targeting Tissue Factor Antibody-Drug Conjugate, in Patients with Advanced Solid Tumours
Ovarian, Endometrial, NSCLC
ZWI-ZW191-101
A Phase 1, Open-label, Multicenter Study to Assess the Safety, Tolerability, Pharmacokinetics, and Preliminary Anti-tumor Activity of Ascending Doses of a Folate Receptor Alpha Antibody Drug Conjugate, ZW191, in Participants with Advanced Solid Tumors
Advanced Solid Tumours with KRAS Mutation or Amplification
BGB-53038-101
A Phase 1a/1b Study to Investigate the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics, and Preliminary Antitumor Activity of BGB-53038, a Pan-KRAS Inhibitor, as Monotherapy or in Combinations in Patients With Advanced or Metastatic Solid Tumors With KRAS Mutations or Amplification
Non-Hodgkin Lymphoma, Chronic Lymphocytic Leukemia
BGB-16673-104
A Phase 1b/2, Open-Label, Master Protocol Study of BTK-Degrader BGB-16673 in Combination With Other Agents in Patients With Relapsed or Refractory B-Cell Malignancies
Advanced PRAME Positive Cancers
IMC-P115C-1005
A Phase 1 First-in-Human Study of the Safety and Efficacy of IMC-P115C as a Single Agent and in Combination with Standard of Care Agents in HLA-A*02:01 Positive Participants with Advanced PRAME Positive Cancers
Platinum-Resistant Ovarian, Peritoneal or Fallopian Tube Cancer
ZN-C3-002
A Phase 1b Study of ZN-c3 in Combination With Chemotherapy in Patients With Platinum-Resistant Ovarian, Peritoneal or Fallopian Tube Cancer
Oncology Patient Referral Form